De PalmaR., Del GaldoF., AbbateG.Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism.Circulation2006; 113: 640–6.
2.
LeitingerN.Oxidized phospholipids as modulators of inflammation in atherosclerosis.Curr Opin Lipidol2003; 14: 421–30.
MuzioM., NatoliG., SaccaniS., LevreroM., MantovaniA.The human toll signaling pathway: divergence of NF- B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6.J Exp Med1998; 187: 2097–101.
6.
XuQ.Role of heat shock protein in atherosclerosis.Arterioscler Thromb Vasc Biol2002; 22: 1547–9.
7.
MillerY.I., ChangM.K., BinderC.J., ShawP.X., WitztumJ.L.Oxidized low density lipoprotein and innate immune receptor.Curr Opin Lipidol2003; 14: 437–45.
8.
FrostegardJ., UlfragenA.K., NybergP.Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines.Atherosclerosis1999; 145: 33–43.
LiuzzoG., BiasucciL.M., RebuzziA.G.Plasma acute-phase response in unstable angina is not induced by ischemic injury.Circulation1996; 94: 2373–80.
11.
LauratE., PoirierB., TupinE.In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice.Circulation2001; 104: 197–202.
12.
StemmeS., FaberB., HolmJ., WiklundO., WitztumJ.L., HanssonG.K.T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.Proc Natl Acad Sci U S A1995; 92: 3893–7.
13.
Yla-HerttualaS., PalinskiW., ButlerS.W., PicardS., SteinbergD., WitztumJ.L.Rabbit and human atherosclerotic lesions contain IgG that recognize epitopes of oxidized LDL.Arterioscler Thromb1994; 14: 32–40.
14.
SaikkuP, LeinonenM., MattilaK.Serological evidence of an association of novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.Lancet1988; 2: 983–6.
15.
HuH., PierceG.N., ZhongG.The atherogenic effect of chlamydia are dependent on serum cholesterol and specific to chlamydia pneumoniae.J Clin Invest1999; 103: 747–53.
16.
CaligiuriG., RottenbergM., NicolettiA., WigzellH., HanssonG.K.Chlamydia pneumoniae infection does not induce or modifies atherosclerosis in mice.Circulation2001; 103: 2834–8.
17.
KalayogluM.V., LibbyB., ByrneG.I.Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.JAMA2002; 288: 2724–31.
18.
PershinkaH., MayrM., MillonigG.Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis.Arterioscler Thromb Vasc Biol2003; 23: 1060–5.
19.
O'ConnorC.M., DunneM.V., PfefferM.A.Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.JAMA2003; 290: 1459–66.
20.
CercekB., ShahP.K., NocM.Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the azithromycin in acute coronary syndrome (AZACS) trial: a randomised controlled trial.Lancet2003; 361: 809–13.
21.
GraystonJ.T., KronmalR.A., JacksonL.A.Azithromycin for secondary prevention of coronary events.N Engl J Med2005; 352: 1637–45.
22.
CannonC.P., BraunwaldE., McCabeC.H.Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome.N Engl J Med2005; 352: 1646–54.
HsichE., ZhouY.F., PaigenB., JohnsonT.M., BurnettM.S., EpsteinS.E.Cytomegalovirus infection increases development of atherosclerosis in apolipoprotein-E knockout mice.Atherosclerosis2001; 156: 23–8.
26.
KolA., LichtmanA.H., FinbergR.W., LibbyP., Kurt-JonesE.A.Heat shock protein (HSP) 60 activates the innate immune response; CD14 is an essential receptor for HSP60 activation of mononuclear cells.J Immunol2000; 164: 13–7.
27.
LiuzzoG., BiasucciL.M., GallimoreJ.R.The prognostic value of C-reactive protein and serum amyloid A in severe unstable angina.Circulation1996; 94: 2373–80.
28.
LindhalB., TossH., SiegbahnA., VengeP., WallentinL.Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease.N Engl J Med2000; 343: 1139–47.
29.
WilcoxJ.N., SmithK.M., SchwartzS.M., GordonD.Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proc Natl Acad Sci U S A1989; 86: 2839–43.
30.
LibbyP.The molecular bases of the acute coronary syndromes.Circulation1995; 91: 2844–50.
31.
AmentoE.P., EhsaniN., PalmerH., LibbyP.Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.Arterioscler Thromb1991; 11: 1223–30.
32.
GalisZ., SuknoveG., LarkM., LibbyP.Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.J Clin Invest1994; 94: 2493–503.
33.
NikkariS.T., O'BrienK.D., FergusonM.Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis.Circulation1995; 92: 1393–8.
34.
SukhoveG.K., SchonbeckU., RabkinE.Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.Circulation1999; 99: 2503–9.
35.
GalisZ., MuszynskyM., LibbyP.Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion.Circ Res1994; 75: 181–9.
36.
DaviesM.J., RichardsonP.D., WoolfN., KatzD.R., MannJ.Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages and smooth muscle cell content.Br Heart J1993; 69: 377–81.
37.
Van der WalA.C., BeckerA.E., van der LoosC.M., DasP.K.Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.Circulation1994; 89: 36–44.
38.
ChengG.C., LoreeH.M., KammR.D., FishbeinM.C., LeeR.T.Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathologic correlation.Circulation1993; 87: 1179–87.
39.
DaviesM.J.Stability and instability: two faces of coronary atherosclerosis: The Paul Dudly White Lecture.Circulation1996; 94: 2013–20.
40.
FarbA., BurkeA., TangA.Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death.Circulation1996; 93: 1354–63.
41.
SlowikM.R., MinW., ArditoT., KarsanA., KashgarianM., PoberJS.Evidence that TNF triggers apoptosis in human endothelial cells by IL-1-converting enzyme-like protease-dependent and -independent pathways.Lab Invest1997; 77: 257–67.
42.
BourcierT., LibbyP.HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression bu human vascular smooth muscle and endothelial cells.Arterioscler Thromb Vasc Biol2000; 20: 556–62.
43.
De CaterinaR., LibbyP., PengH.B.Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.J Clin Invest1995; 96: 60–8.
44.
PengH.B., LibbyP., LiaoJ.K.Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.J Biol Chem1995; 270: 14214–9.
45.
ThurbergB., CollinsT.The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis.Curr Opin Lipidol1998; 9: 387–96.
46.
ZhouX., PaulssonG., StemmeS., HanssonG.K.Hypercholesterolemia is associated with Th1/Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice.J Clin Invest1998; 101: 1717–25.
47.
UyemuraK., DemerK., CastleS.C.Cross regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.J Clin Invest1996; 97: 2130–8.
48.
MosmanT.R., CoffmanR.L.Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties.Annu Rev Immunol1989; 7: 145–73.
49.
FiorentinoD.F., BondM.W., MosmannT.R.Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.J Exp Med1989; 170: 2081–95.
50.
MallatZ., CorbazA., ScoazecA.Expression of IL-18 in human atherosclerotic plaque and relation to plaque instability.Circulation2001; 104: 1598–603.
51.
MallatZ., CorbazA., ScoazecA.IL-18/IL-18 binding protein signaling modulates atherosclerotic lesion development and stability.Circ Res2001; 89: e41–5.
MallatZ., BesnardS., DuriezM.Protective role of IL-10 in atherosclerosis.Circ Res1999; 85: e17–24.
54.
PinderskiL.J., FischbeinM.P., SubbanagounderG.Over expression of IL-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor deficient mice by altering lymphocyte and macrophage phenotypes.Circ Res2002; 90: 1064–71.
55.
CaligiuriG., RudlingM., OllivierV.IL-10 deficiency increases atherosclerosis, thrombosis and LDL in apolipoprotein E-knockout mice.Mol Med2003; 9: 10–7.
56.
RobertsonA.K.L., RudlingM., ZhouX., GorelikL., FlavellR.A., HanssonG.K.Disruption of TGF- signaling in T cells accelerates atherosclerosis.J Clin Invest2003; 112: 1342–50.
57.
FedeleM., VercellinoM., FabbiP.Evaluation of immuneinflammatory response in coronary atherosclerosis.Ital Heart J2006; 7(suppl 1): 12 (abst).
58.
PalinskiW., MillerE., WitztumJ.L.Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malonildialdehyde-modified LDL reduced atherogenesis.Proc Natl Acad Sci U S A1995; 92: 821–5.
59.
FreigangS., HorkkoS., MillerE., WitztumJ.L., PalinskiW.Immunization of LDL receptor-deficient mice with homologous malonildialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanism other than induction of high titers of antibodies to oxidative neoepitopes.Arterioscler Thromb Vasc Biol1998; 18: 1972–82.
60.
AmeliS., Hultgardh-NilssonA., RegnstromJ.Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits.Arterioscler Thromb Vasc Biol1996; 16: 1074–9.
61.
ZhouX., CaligiuriG., HamstenA., LefvertA.K., HanssonG.K.LDL immunization induces T-cells dependent antibody formation and protection against atherosclerosis.Arterioscler Thromb Vasc Biol2001; 21: 108–14.
62.
CaligiuriG., NicolettiA., PoirierB., HanssonG.K.Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice.J Clin Invest2002; 109: 745–53.
63.
BinderC.J., HorkkoS., DewanA.Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL.Nat Med2003; 9: 736–43.
64.
WitztumJ.L.Splenic immunity and atherosclerosis.A glimpse into a novel paradigm? J Clin Invest2002; 109: 721–4.
65.
JonassonL., HolmJ., HanssonJ.K.Cyclosporine A inhibits smooth muscle proliferation in the vascular response to injury.Proc Natl Acad Sci U S A1988; 85: 2303–6.
66.
GalloR., PadureanA., JayaramanT.Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.Circulation1999; 99: 2164–70.
67.
MarxS.O., MarksA.R.Bench to bedside: the development of rapamycin and its application to stent restenosis.Circulation2001; 104: 852–5.
68.
BresalierR.S., SandlerR.S., QuanQ.Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N Engl J Med2005; 352: 1092–102.
69.
TakemotoM., LiaoJ.K.Pleiotropic effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.Arterioscler Thromb Vasc Biol2001; 21: 1712–9.
70.
CrisbyM., Nordin-FriedrikssonG., ShahP.K., YanoJ., ZhuJ., NilssonJ.Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques: implication for plaque stabilization.Circulation2001; 103: 926–33.
71.
SpositoA.C., ChapmanM.J.Statin therapy in acute coronary syndrome: mechanistic insight into clinical benefit.Arterioscler Thromb Vasc Biol2002; 22: 1524–34.
72.
EhrensteinM.R., JuryE.C., MauriC.Statins for atherosclerosis -as good as it gets?.N Engl J Med2005; 352: 73–5.
73.
YoussefS., StuveO., PatarroyoJ.C.The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverse paralysis in central nervous system autoimmune disease.Nature2002; 420: 78–84.
74.
McCareyD.W., McInnesI.B., MadhokR.Trial of atorvastatin in rheumatoid arthriti (TARA): double blind, randomised placebo-controlled trial.Lancet2004; 363: 2015–21.
75.
KwakB., MulhauptF., MyitS., MachF.Statins as a newly recognized type of immunomodulator.Nat Med2000; 6: 1399–402.
76.
RidkerP.M., CannonC.P., MorrowD.C-reactive protein levels and outcomes after statin therapy.N Engl J Med2005; 352: 20–8.
NilssonJ., HanssonG.K., ShahP.K.Immunomodulation of atherosclerosis: implication for vaccine development.Arterioscler Thromb Vasc Biol2005; 25: 18–28.
79.
FredriksonG.N., SoderbergI., LindholmM.Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.Arterioscler Thromb Vasc Biol2003; 23: 879–84.
80.
HaratsD., YacovN., GilburdB., ShoenfeldY., GeorgeJ.Oral tolerance with heat shock protein 65 attenuates mycobacterium tuberculosis-induced and high-fat-driven atherosclerotic lesions.J Am Coll Cardiol2002; 40: 1333–8.
81.
MaronR., SukhovaG., FariaA.M.Mucosal administration of heat shock protein 65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice.Circulation2002; 106: 1708–15.
